Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus chemotherapy as neoadjuvant therapy for locally advanced oral squamous cell carcinoma
ChiCTR2500113229Phase 2Not yet recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in Oral Mucosal Carcinoma, sponsored by The First Hospital of Fujian Medical University. Primary endpoint: pathologic complete response (pCR). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on ChiCTR2500113229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113229.